Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying specific stocks in the market. We monitor 13F filings and institutional buying patterns because large investors often have superior information and research capabilities. We provide ownership data, fund flow analysis, and institutional positioning for comprehensive coverage. Follow institutional money with our comprehensive ownership tracking and analysis tools for smarter investment decisions.
CRISPR Therapeutics AG Common Shares (CRSP), a gene editing-focused biotech firm, is trading at $49.15 as of April 6, 2026, marking a 0.73% decline from the prior close. This analysis covers recent market context for the stock, key technical levels to monitor, and potential near-term price scenarios for investors tracking the name. No recent earnings data is available for CRSP as of the current date, so recent price action has been driven primarily by sector sentiment and technical trading flows
Will CRISPR Thera (CRSP) Stock Hit Record Highs | Price at $49.15, Down 0.73% - Analyst Upgrade
CRSP - Stock Analysis
3,871 Comments
1,331 Likes
1
Hanady
Registered User
2 hours ago
I’m looking for others who noticed this early.
👍 284
Reply
2
Kaizly
Active Reader
5 hours ago
Anyone else just got here?
👍 276
Reply
3
Yanilen
Returning User
1 day ago
Who else has been following this silently?
👍 71
Reply
4
Margueritt
Engaged Reader
1 day ago
I need to find people on the same page.
👍 143
Reply
5
Shemuel
Regular Reader
2 days ago
Anyone else trying to catch up?
👍 30
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.